Nearly a year ago, Rivus Pharmaceuticals unveiled a $132 million Series B round of financing to support mid-stage clinical development of drugs it calls controlled metabolic accelerators.

Source: https://medcitynews.com/2023/08/still-hungry-for-new-obesity-meds-novo-nordisk-makes-another-ma-deal/

This is more than evident with France’s Mistral, the generative AI startup that raised €105 million just one month after founding (and last week raised a further €385 million), and Germany’s Aleph Alpha bagging €500 million in its Series B round.

Source: https://thenextweb.com/news/european-tech-2024-optimism